AdminMar 25, 2020< 1 min read

Empirical Assessment of Privacy Risks in Data

2020-03-05-Empirical-Assessment-of-Privacy-Risks-in-Data

Khaled El Emam, SVP & GM, Replica Analytics; Janice Branson, Global Head of Advanced Methodology & Data Science, Novartis; Nathan Good, Principal, Good Research

Presentation on our experiences with trying to identify individuals in datasets that have been de-personalized, especially health data. This is an overview of Motivated Intruder Attacks.

View Slides

Following the acquisition of Replica Analytics by Aetion, the generative AI technology previously known as Replica Synthesis is now Aetion® Generate and continues to create privacy-enhancing synthetic data.

Learn More

AdminJun 10, 2025< 1 min read

Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study

Recruitment shortfalls are a major reason clinical trials fail, often leading to underpowered studies and inconclusive results. ...

Start Reading

AdminJun 10, 2025< 1 min read

Rescuing Low Accrual Clinical Trials with Generative Models

Patient recruitment shortfalls threaten trial success, leading to underpowered studies, increased patient risk, and wasted ...

Start Reading

Natalie Schibell, MPHJun 9, 20254 min read

The Key Takeaway from the AWS Life Sciences Symposium: Data Alone Is Not Enough—Evidence Matters

More than 1,000 leaders from healthcare and life sciences gathered in New York City on May 20–21, 2025, for the seventh annual ...

Start Reading

SOFTWARE

SERVICES

PARTNERSHIPS

Empirical Assessment of Privacy Risks in Data

RELATED ARTICLES

Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study

Rescuing Low Accrual Clinical Trials with Generative Models

The Key Takeaway from the AWS Life Sciences Symposium: Data Alone Is Not Enough—Evidence Matters